(Q28301659)

6

Yilmaz Cakaloglu

0 references

Guido Gerken

Guido Gerken

9

0 references

Bettina Hansen

Bettina Hansen

13

0 references

Krzysztof Simon

1 reference

ORCID Public Data File 2021

Hubert G.M. Niesters

11

Hubert G M Niesters

0 references

author name string

Harry L A Janssen

1

0 references

Monika van Zonneveld

2

0 references

Hakan Senturk

3

0 references

Ulus S Akarca

5

0 references

Christopher Simon

7

0 references

Thomas M K So

8

0 references

Robert A de Man

10

0 references

Pieter Zondervan

12

0 references

Solko W Schalm

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa

14

0 references

language of work or name

English

0 references

publication date

January 2005

1 reference

0 references

365

0 references

issue

9454

0 references

page(s)

123-9

0 references

uses

randomized experiment

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Long-term remission of chronic hepatitis B after alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Hepatitis B virus immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2917701-0

7 January 2021

10.1016/S0140-6736(05)17701-0

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

release_b53wnf34zrhwnem2xo5gvzq7ju

125659

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b53wnf34zrhwnem2xo5gvzq7ju

24 November 2022

mapped directly with Wikidata item

125659

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference